Platelet-activating factor acetylhydrolases in health and disease.
about
To hydrolyze or not to hydrolyze: the dilemma of platelet-activating factor acetylhydrolaseAntioxidant and inflammatory aspects of lipoprotein-associated phospholipase A₂ (Lp-PLA₂): a reviewCrystal Structure of Human Plasma Platelet-activating Factor Acetylhydrolase: STRUCTURAL IMPLICATION TO LIPOPROTEIN BINDING AND CATALYSISThe role of platelet-activating factor in mesangial pathophysiologyLIS1 regulates osteoclast formation and function through its interactions with dynein/dynactin and Plekhm1YY-1224, a terpene trilactone-strengthened Ginkgo biloba, attenuates neurodegenerative changes induced by β-amyloid (1-42) or double transgenic overexpression of APP and PS1 via inhibition of cyclooxygenase-2.Proteomic analysis of differential protein expression in atherosclerosis.Role of group V phospholipase A2 in zymosan-induced eicosanoid generation and vascular permeability revealed by targeted gene disruption.PAF acetylhydrolase gene polymorphisms and asthma severity.Experimental and emerging therapies for sepsis and septic shock.Drotrecogin alfa: a new approach in the treatment of severe sepsis.Biology of platelet-activating factor acetylhydrolase (PAF-AH, lipoprotein associated phospholipase A2).Urothelial cell platelet-activating factor production mediated by calcium-independent phospholipase A2γ.Biological role of Trichoderma harzianum-derived platelet-activating factor acetylhydrolase (PAF-AH) on stress response and antagonism.Oligomeric state regulated trafficking of human platelet-activating factor acetylhydrolase type-II.Trafficking of platelet-activating factor acetylhydrolase type II in response to oxidative stress.Cigarette smoke induces cell motility via platelet-activating factor accumulation in breast cancer cells: a potential mechanism for metastatic disease.Lipoprotein associated phospholipase A2 activity & its correlation with oxidized LDL & glycaemic status in early stages of type-2 diabetes mellitusPlatelet-activating factor, a pleiotrophic mediator of physiological and pathological processes.Patients with early rheumatoid arthritis exhibit elevated autoantibody titers against mildly oxidized low-density lipoprotein and exhibit decreased activity of the lipoprotein-associated phospholipase A2.Antithrombotic and antiatherosclerotic properties of olive oil and olive pomace polar extracts in rabbits.Lung endothelial cell platelet-activating factor production and inflammatory cell adherence are increased in response to cigarette smoke component exposure.Lipopolysaccharide Cross-Tolerance Delays Platelet-Activating Factor-Induced Sudden Death in Swiss Albino Mice: Involvement of Cyclooxygenase in Cross-ToleranceCandidate-based proteomics in the search for biomarkers of cardiovascular disease.Impact of atorvastatin treatment on platelet-activating factor acetylhydrolase and 15-F(2trans)-isoprostane in hypercholesterolaemic patients.Preliminary Proteomic Analysis of A549 Cells Infected with Avian Influenza Virus H7N9 and Influenza A Virus H1N1Platelet-activating factor in liver injury: a relational scopeMultiple roles of phospholipase A2 during lung infection and inflammation.Predicting the risk of cardiovascular disease: where does lipoprotein-associated phospholipase A(2) fit in?The prevalence of platelet activating factor acetylhydrolase single nucleotide polymorphisms in relationship to necrotizing enterocolitis in Northwest Louisiana infants.LIS1 Regulates Osteoclastogenesis through Modulation of M-SCF and RANKL Signaling Pathways and CDC42.Receptor-dependent metabolism of platelet-activating factor in murine macrophages.Molecular characterization of the constitutive expression of the plasma platelet-activating factor acetylhydrolase gene in macrophages.Effect of fenofibrate on serum inflammatory markers in patients with high triglyceride values.Modifications of plasma platelet-activating factor (PAF)-acetylhydrolase/PAF system activity in patients with chronic hepatitis C virus infection.Design of new secreted phospholipase A2 inhibitors based on docking calculations by modifying the pharmacophore segments of the FPL67047XX inhibitor.Platelet-activating factor synthesis and receptor-mediated signaling are downregulated in ovine newborn lungs: relevance in postnatal pulmonary adaptation and persistent pulmonary hypertension of the newborn.Spatial and temporal coordination of expression of immune response genes during Pseudomonas infection of horseshoe crab, Carcinoscorpius rotundicauda.Altered distribution of plasma PAF-AH between HDLs and other lipoproteins in hyperlipidemia and diabetes mellitus.Platelet-activating factor (PAF) in internal jugular venous blood of migraine without aura patients assessed during migraine attacks.
P2860
Q26865969-FD2C635B-4B39-4CE6-827C-8ACC1D193175Q26991853-103802EC-FE81-4E9E-B648-9468D22978EAQ27652078-47AA6AE6-C9C2-496D-9597-865FEC7A21A6Q28081511-BF1E778C-64FA-4137-809D-11E0E01FC40DQ28593263-33E89683-97FB-435A-AF37-4A9AC72DB791Q30847206-11223D73-B578-4980-9D62-49E956C420CCQ33246067-38997F67-6888-4022-86F9-B99A567AF8CCQ33947290-C81D3F2B-F8FA-4694-9198-101556612CA2Q34355213-A5303098-5289-4BA0-99B6-F1C042D2B05BQ34481636-C34FF9CC-61F1-4D42-9050-78FC114DFD05Q34779800-F63CA1B4-85EC-432A-ACA6-81107F86A639Q34864975-5AB71DEA-9E64-44C7-9E0C-A29AE2EBC947Q34923053-06D8E317-4892-4E18-ADBB-6B12D5AD745CQ35194781-C7483999-6BA2-4722-BBEC-8D0D86C006BBQ35236551-045B6439-9832-424F-B688-942B3FC86A42Q35243182-93AE431B-9310-4FA1-9CC8-4C1237F99928Q35363053-94A81F87-57D8-4780-A833-2FEF715C4AA0Q35520145-E3C8729F-9CA8-4BD1-9639-E726F2407523Q35621992-32195676-C8B5-49ED-966F-6ACFA2AC0006Q35769101-02C7D927-61F0-4771-BCB4-29F9DA56AD36Q35925371-F14D7A2E-1D98-40B3-A327-4DE94051D599Q35950191-4F046047-73A2-45A5-BC72-479DCE802B38Q35985649-46352C39-7087-4092-8CCB-6B9A95F2CAF9Q35990040-EA3F88C5-0568-44A5-BE5C-05F87F0B15F6Q36024430-C398A38A-4C64-4CD9-80F6-0D84B8F29700Q36029125-81C11B7E-FD83-4482-ABF0-4FD6F1F56297Q36506462-0E147D04-F946-47C3-A050-2C28C1967998Q36710691-F1D9CEE4-1648-4C4D-A9BC-70C2772ED51DQ36913018-798A28F2-A9A4-4C0E-92F0-A5E30E219FADQ37009251-8FEF544F-084B-401E-8691-4EBE821AEA20Q37513913-50C8E799-CF34-4021-A751-28B6744101DCQ38293081-69E2B583-081A-4839-B4CE-851A7DD8B34FQ38352665-53CB4EAD-4720-4087-98B2-559AE7E5D527Q40516350-7460BE56-8816-469B-B316-EA6F417EB13EQ43035003-F9C2CE3F-A96C-45F7-893F-6F52BB08D907Q43174214-1D4077C8-F2C4-4562-81E9-1EA1AF5D49A3Q43442990-245F0F3C-48FE-4FE4-BF98-0F456056C9A5Q43520358-F6C0E311-F0DF-4A86-B26C-11FB7C208502Q44516292-17AF14C0-C5F5-48BF-B49D-69199054BEEEQ44986607-7071247E-FBCB-407C-B376-7DF59C638921
P2860
Platelet-activating factor acetylhydrolases in health and disease.
description
2000 nî lūn-bûn
@nan
2000 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
Platelet-activating factor acetylhydrolases in health and disease.
@ast
Platelet-activating factor acetylhydrolases in health and disease.
@en
Platelet-activating factor acetylhydrolases in health and disease.
@nl
type
label
Platelet-activating factor acetylhydrolases in health and disease.
@ast
Platelet-activating factor acetylhydrolases in health and disease.
@en
Platelet-activating factor acetylhydrolases in health and disease.
@nl
prefLabel
Platelet-activating factor acetylhydrolases in health and disease.
@ast
Platelet-activating factor acetylhydrolases in health and disease.
@en
Platelet-activating factor acetylhydrolases in health and disease.
@nl
P1476
Platelet-activating factor acetylhydrolases in health and disease.
@en
P2093
D M Stafforini
L W Tjoelker
P304
P356
10.1016/S1388-1981(00)00114-1
P407
P577
2000-10-01T00:00:00Z